CoChat
Sign Up
Cited by 6,879Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsHeart rate and cardiovascular health

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

Authors/Task Force Members, McMurray, John J.V., Adamopoulos, Stamatis, Anker, Stefan D., Auricchio, Angelo, Böhm, Michael, Dickstein, Kenneth, Falk, Volkmar, Filippatos, Gerasimos, Fonseca, Cândida, Gomez-Sanchez, Miguel Angel, Jaarsma, Tiny, Køber, Lars, Lip, Gregory Y.H., Maggioni, Aldo Pietro, Parkhomenko, Alexander, Pieske, Burkert M., Popescu, Bogdan A., Rønnevik, Per K., Rutten, Frans H., Schwitter, Juerg, Seferovic, Petar, Stepinska, Janina, Trindade, Pedro T., Voors, Adriaan A., Zannad, Faiez, Zeiher, Andreas, ESC Committee for Practice Guidelines (CPG), Bax, Jeroen J., Baumgartner, Helmut, Ceconi, Claudio, Dean, Veronica, Deaton, Christi, Fagard, Robert, Funck-Brentano, Christian, Hasdai, David, Hoes, Arno, Kirchhof, Paulus, Knuuti, Juhani, Kolh, Philippe, McDonagh, Theresa, Moulin, Cyril, Popescu, Bogdan A., Reiner, Željko, Sechtem, Udo, Sirnes, Per Anton, Tendera, Michal, Torbicki, Adam, Vahanian, Alec, Windecker, Stephan, Document Reviewers, McDonagh, Theresa, Sechtem, Udo, Bonet, Luis Almenar, Avraamides, Panayiotis, Ben Lamin, Hisham A., Brignole, Michele, Coca, Antonio, Cowburn, Peter, Dargie, Henry, Elliott, Perry, Flachskampf, Frank Arnold, Guida, Guido Francesco, Hardman, Suzanna, Iung, Bernard, Merkely, Bela, Mueller, Christian, Nanas, John N., Nielsen, Olav Wendelboe, Ørn, Stein, Parissis, John T., Ponikowski, Piotr·2012·European Heart Journal
DOI 10.1093/eurheartj/ehs104
Open this paper in CoChat — free account

Abstract

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehs104

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 48 references

Research works printed but not linked: 225

  1. Dickstein, 2008, ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM), Eur J Heart Fail, 10, 933, 10.1016/j.ejheart.2008.08.005 · DOI
  2. Davie, 1997, Assessing diagnosis in heart failure: which features are any use?, QJM, 90, 335, 10.1093/qjmed/90.5.335 · DOI
  3. Oudejans, 2011, Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests, Eur J Heart Fail, 13, 518, 10.1093/eurjhf/hfr021 · DOI
  4. Fonseca, 2006, Diagnosis of heart failure in primary care, Heart Fail Rev, 11, 95, 10.1007/s10741-006-9481-0 · DOI
  5. Kelder, 2011, The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure, Circulation, 124, 2865, 10.1161/CIRCULATIONAHA.111.019216 · DOI
  6. Borlaug, 2011, Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment, Eur Heart J, 32, 670, 10.1093/eurheartj/ehq426 · DOI
  7. Paulus, 2007, How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology, Eur Heart J, 28, 2539, 10.1093/eurheartj/ehm037 · DOI
  8. Marwick, 2010, Recent developments in heart failure imaging, JACC Cardiovasc Imaging, 3, 429, 10.1016/j.jcmg.2010.02.002 · DOI
  9. Paterson, 2011, Recent advances in cardiac imaging for patients with heart failure, Curr Opin Cardiol, 26, 132, 10.1097/HCO.0b013e32834380e7 · DOI
  10. McMurray, 2010, Systolic heart failure, N Engl J Med, 362, 228, 10.1056/NEJMcp0909392 · DOI
  11. Chen, 2011, National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008, JAMA, 306, 1669, 10.1001/jama.2011.1474 · DOI
  12. Dunlay, 2009, Hospitalizations after heart failure diagnosis a community perspective, J Am Coll Cardiol, 54, 1695, 10.1016/j.jacc.2009.08.019 · DOI
  13. Khot, 2003, Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification, JAMA, 290, 2174, 10.1001/jama.290.16.2174 · DOI
  14. Mosterd, 2007, Clinical epidemiology of heart failure, Heart, 93, 1137, 10.1136/hrt.2003.025270 · DOI
  15. Ackerman, 2011, HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA), Heart Rhythm, 8, 1308, 10.1016/j.hrthm.2011.05.020 · DOI
  16. Hogg, 2004, Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis, J Am Coll Cardiol, 43, 317, 10.1016/j.jacc.2003.07.046 · DOI
  17. Lam, 2011, Epidemiology and clinical course of heart failure with preserved ejection fraction, Eur J Heart Fail, 13, 18, 10.1093/eurjhf/hfq121 · DOI · Paper page
  18. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC), 2012, The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis, Eur Heart J, 33, 1750, 10.1093/eurheartj/ehr254 · DOI
  19. Shah, 2011, In search of new therapeutic targets and strategies for heart failure: recent advances in basic science, Lancet, 378, 704, 10.1016/S0140-6736(11)60894-5 · DOI
  20. Stewart, 2001, More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure, Eur J Heart Fail, 3, 315, 10.1016/S1388-9842(00)00141-0 · DOI
  21. Stewart, 2010, Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004), Circ Cardiovasc Qual Outcomes, 3, 573, 10.1161/CIRCOUTCOMES.110.957571 · DOI
  22. Jhund, 2009, Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people, Circulation, 119, 515, 10.1161/CIRCULATIONAHA.108.812172 · DOI
  23. Rutten, 2005, Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study, BMJ, 331, 1379, 10.1136/bmj.38664.661181.55 · DOI
  24. Hawkins, 2009, Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology, Eur J Heart Fail, 11, 130, 10.1093/eurjhf/hfn013 · DOI
  25. Daniels, 2006, How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study, Am Heart J, 151, 999, 10.1016/j.ahj.2005.10.011 · DOI
  26. Rudski, 2010, Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography, J Am Soc Echocardiogr, 23, 786
  27. Dokainish, 2011, Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study, Eur J Echocardiogr, 12, 857, 10.1093/ejechocard/jer157 · DOI
  28. Kirkpatrick, 2007, Echocardiography in heart failure: applications, utility, and new horizons, J Am Coll Cardiol, 50, 381, 10.1016/j.jacc.2007.03.048 · DOI
  29. Lancellotti, 2010, European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease), Eur J Echocardiogr, 11, 307, 10.1093/ejechocard/jeq031 · DOI
  30. Lancellotti, 2010, European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease), Eur J Echocardiogr, 11, 223, 10.1093/ejechocard/jeq030 · DOI · Paper page
  31. Popescu, 2009, European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography, Eur J Echocardiogr, 10, 893, 10.1093/ejechocard/jep151 · DOI
  32. Nagueh, 2011, Echocardiographic evaluation of hemodynamics in patients with decompensated systolic heart failure, Circ Cardiovasc Imaging, 4, 220, 10.1161/CIRCIMAGING.111.963496 · DOI
  33. Sicari, 2008, Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC), Eur J Echocardiogr, 9, 415, 10.1093/ejechocard/jen175 · DOI
  34. Davie, 1996, Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction, BMJ, 312, 222, 10.1136/bmj.312.7025.222 · DOI
  35. Thomas, 2002, Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure, Am J Med, 112, 437, 10.1016/S0002-9343(02)01048-3 · DOI
  36. Khunti, 2004, Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis, Eur J Heart Fail, 6, 571, 10.1016/j.ejheart.2004.03.013 · DOI
  37. Madias, 2011, Why recording of an electrocardiogram should be required in every inpatient and outpatient encounter of patients with heart failure, Pacing Clin Electrophysiol, 34, 963, 10.1111/j.1540-8159.2011.03131.x · DOI
  38. Ewald, 2008, Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction, Intern Med J, 38, 101, 10.1111/j.1445-5994.2007.01454.x · DOI
  39. Doust, 2004, A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure, Arch Intern Med, 164, 1978, 10.1001/archinte.164.18.1978 · DOI
  40. Zaphiriou, 2005, The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study, Eur J Heart Fail, 7, 537, 10.1016/j.ejheart.2005.01.022 · DOI · Paper page
  41. Fuat, 2006, The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure, Br J Gen Pract, 56, 327
  42. Yamamoto, 2000, Clinical criteria and biochemical markers for the detection of systolic dysfunction, J Card Fail, 6, 194, 10.1054/jcaf.2000.9676 · DOI
  43. Cowie, 1997, Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care, Lancet, 350, 1349, 10.1016/S0140-6736(97)06031-5 · DOI
  44. Krishnaswamy, 2001, Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction, Am J Med, 111, 274, 10.1016/S0002-9343(01)00841-5 · DOI
  45. Kelder, 2011, Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis, Heart, 97, 959, 10.1136/hrt.2010.220426 · DOI
  46. Kelder, 2011, Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure, J Card Fail, 17, 729, 10.1016/j.cardfail.2011.04.013 · DOI
  47. Gustafsson, 2005, Diagnostic and prognostic performance of N-terminal proBNP in primary care patients with suspected heart failure, J Card Fail, 11, S15, 10.1016/j.cardfail.2005.04.022 · DOI
  48. Nielsen, 2004, Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability, Scand J Clin Lab Invest, 64, 619, 10.1080/00365510410002878 · DOI
  49. Maisel, 2010, Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial, J Am Coll Cardiol, 55, 2062, 10.1016/j.jacc.2010.02.025 · DOI
  50. Schwitter, 2008, Extending the frontiers of cardiac magnetic resonance, Circulation, 118, 109, 10.1161/CIRCULATIONAHA.108.790139 · DOI
  51. Gebker, 2007, How we perform myocardial perfusion with cardiovascular magnetic resonance, J Cardiovasc Magn Reson, 9, 539, 10.1080/10976640600897286 · DOI
  52. Beller, 2011, SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability, J Cardiovasc Transl Res, 4, 416, 10.1007/s12265-011-9290-2 · DOI
  53. Leong, 2010, Heart failure with normal ejection fraction: the complementary roles of echocardiography and CMR imaging, JACC Cardiovasc Imaging, 3, 409, 10.1016/j.jcmg.2009.12.011 · DOI
  54. Myerson, 2009, Valvular and hemodynamic assessment with CMR, Heart Fail Clin, 5
  55. Raman, 2009, The CMR examination in heart failure, Heart Fail Clin, 5
  56. Sheikine, 2008, Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure, Curr Heart Fail Rep, 5, 136, 10.1007/s11897-008-0022-0 · DOI
  57. Miller, 2008, Diagnostic performance of coronary angiography by 64-row CT, N Engl J Med, 359, 2324, 10.1056/NEJMoa0806576 · DOI
  58. Beanlands, 2007, F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2), J Am Coll Cardiol, 50, 2002, 10.1016/j.jacc.2007.09.006 · DOI
  59. Lang, 2006, Recommendations for chamber quantification, Eur J Echocardiogr, 7, 79, 10.1016/j.euje.2005.12.014 · DOI
  60. Nagueh, 1997, Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures, J Am Coll Cardiol, 30, 1527, 10.1016/S0735-1097(97)00344-6 · DOI
  61. Schwitter, 2011, Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance, Eur Heart J, 32, 799, 10.1093/eurheartj/ehq481 · DOI
  62. Kilner, 2010, Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology, Eur Heart J, 31, 794, 10.1093/eurheartj/ehp586 · DOI
  63. Luchinger, Safety of CMR
  64. Bruder, 2011, Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients. from the EuroCMR Registry, J Am Coll Cardiol-Cardiovasc Imaging, 4, 1171, 10.1016/j.jcmg.2011.06.019 · DOI
  65. Sheikine, 2008, Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure, Curr Heart Fail Rep, 5, 136, 10.1007/s11897-008-0022-0 · DOI
  66. Tonino, 2009, Fractional flow reserve versus angiography for guiding percutaneous coronary intervention, N Engl J Med, 360, 213, 10.1056/NEJMoa0807611 · DOI
  67. Wijns, 2010, Guidelines on myocardial revascularization, Eur Heart J, 31, 2501, 10.1093/eurheartj/ehq277 · DOI
  68. Cooper, 2007, The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology, Eur Heart J, 28, 3076, 10.1093/eurheartj/ehm456 · DOI
  69. Arena, 2011, Cardiopulmonary exercise testing is a core assessment for patients with heart failure, Congest Heart Fail, 17, 115, 10.1111/j.1751-7133.2011.00216.x · DOI
  70. Wedel, 2009, Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide, Eur J Heart Fail, 11, 281, 10.1093/eurjhf/hfn046 · DOI
  71. Allen, 2009, Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program, Eur J Heart Fail, 11, 170, 10.1093/eurjhf/hfn031 · DOI
  72. Jackson, 2009, Albuminuria in chronic heart failure: prevalence and prognostic importance, Lancet, 374, 543, 10.1016/S0140-6736(09)61378-7 · DOI
  73. Felker, 2007, Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank, J Am Coll Cardiol, 50, 40, 10.1016/j.jacc.2007.02.067 · DOI
  74. Pocock, 2006, Predictors of mortality and morbidity in patients with chronic heart failure, Eur Heart J, 27, 65, 10.1093/eurheartj/ehi555 · DOI
  75. Komajda, 2011, Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE), Circ Heart Fail, 4, 27, 10.1161/CIRCHEARTFAILURE.109.932996 · DOI
  76. Ketchum, 2011, Establishing prognosis in heart failure: a multimarker approach, Prog Cardiovasc Dis, 54, 86, 10.1016/j.pcad.2011.03.003 · DOI
  77. Stewart, 2002, The current cost of heart failure to the National Health Service in the UK, Eur J Heart Fail, 4, 361, 10.1016/S1388-9842(01)00198-2 · DOI
  78. Masson, 2008, Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial), J Am Coll Cardiol, 52, 997, 10.1016/j.jacc.2008.04.069 · DOI
  79. Wong, 2002, Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study, J Am Coll Cardiol, 40, 970, 10.1016/S0735-1097(02)02063-6 · DOI
  80. Packer, 1993, Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study, J Am Coll Cardiol, 22, 65, 10.1016/0735-1097(93)90816-J · DOI
  81. Cowley, 1989, Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study, Int J Cardiol, 24, 311, 10.1016/0167-5273(89)90010-7 · DOI
  82. Effects of enalapril on mortality in severe congestive heart failure, 1987, Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group, N Engl J Med, 316, 1429
  83. Garg, 1995, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials, JAMA, 273, 1450, 10.1001/jama.1995.03520420066040 · DOI
  84. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, 1999, Lancet, 353, 9, 10.1016/S0140-6736(98)11181-9 · DOI
  85. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), 1999, Lancet, 353, 2001, 10.1016/S0140-6736(99)04440-2 · DOI
  86. Packer, 2002, Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study, Circulation, 106, 2194, 10.1161/01.CIR.0000035653.72855.BF · DOI · Paper page
  87. Flather, 2005, Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS), Eur Heart J, 26, 215, 10.1093/eurheartj/ehi115 · DOI
  88. Packer, 1996, The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group, N Engl J Med, 334, 1349, 10.1056/NEJM199605233342101 · DOI · Paper page
  89. Flather, 2000, Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group, Lancet, 355, 1575, 10.1016/S0140-6736(00)02212-1 · DOI
  90. McMurray, 2005, Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice, Eur J Heart Fail, 7, 710, 10.1016/j.ejheart.2005.07.002 · DOI
  91. Beta-Blocker Evaluation of Survival Trial Investigators, 2001, A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure, N Engl J Med, 344, 1659, 10.1056/NEJM200105313442202 · DOI
  92. Poole-Wilson, 2003, Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial, Lancet, 362, 7, 10.1016/S0140-6736(03)13800-7 · DOI · Paper page
  93. Krum, 2003, Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study, JAMA, 289, 712, 10.1001/jama.289.6.712 · DOI
  94. Jondeau, 2009, B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode, Eur Heart J, 30, 2186, 10.1093/eurheartj/ehp323 · DOI · Paper page
  95. Granger, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial, Lancet, 362, 772, 10.1016/S0140-6736(03)14284-5 · DOI · Paper page
  96. Swedberg, 2010, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study, Lancet, 376, 875, 10.1016/S0140-6736(10)61198-1 · DOI · Paper page
  97. Tavazzi, 2008, Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1223, 10.1016/S0140-6736(08)61239-8 · DOI · Paper page
  98. Pitt, 2000, Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II, Lancet, 355, 1582, 10.1016/S0140-6736(00)02213-3 · DOI
  99. Dickstein, 2002, Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan, Lancet, 360, 752, 10.1016/S0140-6736(02)09895-1 · DOI
  100. Fox, 2008, Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 807, 10.1016/S0140-6736(08)61170-8 · DOI · Paper page
  101. Hood, 2004, Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis, J Card Fail, 10, 155, 10.1016/j.cardfail.2003.12.005 · DOI
  102. 1999, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico, Lancet, 354, 447, 10.1016/S0140-6736(99)07072-5 · DOI · Paper page
  103. Krum, 2011, Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study, Eur J Heart Fail, 13, 107, 10.1093/eurjhf/hfq212 · DOI
  104. Gheorghiade, 2011, Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT), Eur J Heart Fail, 13, 100, 10.1093/eurjhf/hfq209 · DOI
  105. Homma, 2012, Warfarin and aspirin in patients with heart failure and sinus rhythm, N Engl J Med, 10.1056/NEJMoa1202299 · DOI
  106. Hernandez, 2011, Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials, Am J Cardiovasc Drugs, 11, 115, 10.2165/11587580-000000000-00000 · DOI
  107. Erdmann, 2007, Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08), Diabetes Care, 30, 2773, 10.2337/dc07-0717 · DOI
  108. Mamdani, 2004, Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study, Lancet, 363, 1751, 10.1016/S0140-6736(04)16299-5 · DOI
  109. Huerta, 2006, Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population, Heart, 92, 1610, 10.1136/hrt.2005.082388 · DOI
  110. Setaro, 1990, Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance, Am J Cardiol, 66, 981, 10.1016/0002-9149(90)90937-V · DOI
  111. Hung, 2002, Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure, Int J Clin Pract, 56, 57, 10.1111/j.1742-1241.2002.tb11193.x · DOI
  112. Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7 · DOI · Paper page
  113. Cleland, 2006, The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, 2338, 10.1093/eurheartj/ehl250 · DOI
  114. Zipes, 2006, ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society, Eur Heart J, 27, 2099, 10.1093/eurheartj/ehl199 · DOI
  115. 1997, A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators, N Engl J Med, 337, 1576, 10.1056/NEJM199711273372202 · DOI
  116. Kuck, 2000, Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH), Circulation, 102, 748, 10.1161/01.CIR.102.7.748 · DOI
  117. Connolly, 2000, Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone, Circulation, 101, 1297, 10.1161/01.CIR.101.11.1297 · DOI
  118. Oseroff, 2004, Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH), Curr Opin Cardiol, 19, 26, 10.1097/00001573-200401000-00007 · DOI
  119. Moss, 1996, Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators, N Engl J Med, 335, 1933, 10.1056/NEJM199612263352601 · DOI · Paper page
  120. Hohnloser, 2004, Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction, N Engl J Med, 351, 2481, 10.1056/NEJMoa041489 · DOI · Paper page
  121. Steinbeck, 2009, Defibrillator implantation early after myocardial infarction, N Engl J Med, 361, 1427, 10.1056/NEJMoa0901889 · DOI · Paper page
  122. Kadish, 2004, Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy, N Engl J Med, 350, 2151, 10.1056/NEJMoa033088 · DOI
  123. Stewart, 2010, Patient expectations from implantable defibrillators to prevent death in heart failure, J Card Fail, 16, 106, 10.1016/j.cardfail.2009.09.003 · DOI
  124. Cleland, 2005, The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med, 352, 1539, 10.1056/NEJMoa050496 · DOI
  125. Dickstein, 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association, Eur J Heart Fail 2010, 12, 1143
  126. Beshai, 2007, Cardiac-resynchronization therapy in heart failure with narrow QRS complexes, N Engl J Med, 357, 2461, 10.1056/NEJMoa0706695 · DOI
  127. Chung, 2008, Results of the Predictors of Response to CRT (PROSPECT) trial, Circulation, 117, 2608, 10.1161/CIRCULATIONAHA.107.743120 · DOI
  128. Linde, 2008, Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms, J Am Coll Cardiol, 52, 1834, 10.1016/j.jacc.2008.08.027 · DOI
  129. Leclercq, 2002, Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation, Eur Heart J, 23, 1780, 10.1053/euhj.2002.3232 · DOI
  130. Wilton, 2011, Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis, Heart Rhythm, 8, 1088, 10.1016/j.hrthm.2011.02.014 · DOI
  131. Ganesan, 2012, Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure. A systematic review, J Am Coll Cardiol, 59, 719, 10.1016/j.jacc.2011.10.891 · DOI
  132. Tops, 2009, The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy, J Am Coll Cardiol, 54, 764, 10.1016/j.jacc.2009.06.006 · DOI
  133. Vardas, 2007, Guidelines for cardiac pacing and cardiac resynchronization therapy: the Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association, Eur Heart J, 28, 2256, 10.1093/eurheartj/ehm305 · DOI
  134. Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 31, 2369, 10.1093/eurheartj/ehq278 · DOI
  135. Lewis, 1989, Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation, J Cardiovasc Pharmacol, 13, 1, 10.1097/00005344-198901000-00002 · DOI
  136. Khand, 2003, Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?, J Am Coll Cardiol, 42, 1944, 10.1016/j.jacc.2003.07.020 · DOI · Paper page
  137. Lewis, 1988, A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation, Eur Heart J, 9, 279, 10.1093/oxfordjournals.eurheartj.a062497 · DOI
  138. Piepoli, 1998, Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure, Int J Cardiol, 66, 1, 10.1016/S0167-5273(98)00184-3 · DOI
  139. 1997, Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators, Lancet, 350, 1417, 10.1016/S0140-6736(97)05281-1 · DOI
  140. Khan, 2008, Pulmonary-vein isolation for atrial fibrillation in patients with heart failure, N Engl J Med, 359, 1778, 10.1056/NEJMoa0708234 · DOI
  141. MacDonald, 2011, Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial, Heart, 97, 740, 10.1136/hrt.2010.207340 · DOI
  142. Kober, 2008, Increased mortality after dronedarone therapy for severe heart failure, N Engl J Med, 358, 2678, 10.1056/NEJMoa0800456 · DOI
  143. Connolly, 2011, Dronedarone in high-risk permanent atrial fibrillation, N Engl J Med, 365, 2268, 10.1056/NEJMoa1109867 · DOI
  144. Echt, 1991, Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial, N Engl J Med, 324, 781, 10.1056/NEJM199103213241201 · DOI
  145. Lip, 2010, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation, Chest, 137, 263, 10.1378/chest.09-1584 · DOI · Paper page
  146. Pisters, 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 138, 1093, 10.1378/chest.10-0134 · DOI
  147. Hart, 1999, Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis, Ann Intern Med, 131, 492, 10.7326/0003-4819-131-7-199910050-00003 · DOI
  148. Larson, 2004, Should aspirin be continued in patients started on warfarin?, J Gen Intern Med, 19, 879, 10.1111/j.1525-1497.2004.30419.x · DOI
  149. McMurray, 2009, Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial, Eur J Heart Fail, 11, 795, 10.1093/eurjhf/hfp098 · DOI
  150. Packer, 1996, Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group, N Engl J Med, 335, 1107, 10.1056/NEJM199610103351504 · DOI
  151. Wijeysundera, 2003, Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine, Am Heart J, 146, 291, 10.1016/S0002-8703(03)00171-6 · DOI
  152. Yusuf, 1994, Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration, Lancet, 344, 563, 10.1016/S0140-6736(94)91963-1 · DOI
  153. Velazquez, 2011, Coronary-artery bypass surgery in patients with left ventricular dysfunction, N Engl J Med, 364, 1607, 10.1056/NEJMoa1100356 · DOI
  154. Akashi, 2005, Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches, Curr Heart Fail Rep, 2, 198, 10.1007/BF02696650 · DOI
  155. Eschenhagen, 2011, Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail, 13, 1, 10.1093/eurjhf/hfq213 · DOI
  156. Jones, 2009, Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring, Br J Cancer, 100, 684, 10.1038/sj.bjc.6604909 · DOI
  157. Dungen, 2011, Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial, Eur J Heart Fail, 13, 670, 10.1093/eurjhf/hfr020 · DOI
  158. McMurray, 2010, Effect of valsartan on the incidence of diabetes and cardiovascular events, N Engl J Med, 362, 1477, 10.1056/NEJMoa1001121 · DOI · Paper page
  159. Bakris, 2004, Metabolic Effects of carvedilol vs metoprolol in patients with type4 2 diabetes mellitus and hypertension—a randomized contolled trial, JAMA, 292, 2227, 10.1001/jama.292.18.2227 · DOI · Paper page
  160. Guazzi, 2011, PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study, Circ Heart Fail, 4, 8, 10.1161/CIRCHEARTFAILURE.110.944694 · DOI
  161. 2000, Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group, JAMA, 283, 1967, 10.1001/jama.283.15.1967 · DOI
  162. Cohn, 2003, Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON), Eur J Heart Fail, 5, 659, 10.1016/S1388-9842(03)00163-6 · DOI
  163. Cohn, 1997, Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group, Circulation, 96, 856, 10.1161/01.CIR.96.3.856 · DOI
  164. Mancia, 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), Eur Heart J 2007, 28, 1462
  165. Dorszewski, 1997, Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study, J Card Fail, 3, 91, 10.1016/S1071-9164(97)90040-3 · DOI
  166. Bayliss, 1985, Clinical importance of the renin–angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin, Br Med J (Clin Res, 290, 1861, 10.1136/bmj.290.6485.1861 · DOI
  167. Ronco, 2010, Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative, Eur Heart J, 31, 703, 10.1093/eurheartj/ehp507 · DOI
  168. McKelvie, 2011, The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care, Can J Cardiol, 27, 319
  169. Kasai, 2011, Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications, J Am Coll Cardiol, 57, 119, 10.1016/j.jacc.2010.08.627 · DOI
  170. Felker, 2011, Diuretic strategies in patients with acute decompensated heart failure, N Engl J Med, 364, 797, 10.1056/NEJMoa1005419 · DOI
  171. Alikhan, 2003, Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study, Blood Coagul Fibrinolysis, 14, 341, 10.1097/00001721-200306000-00004 · DOI
  172. Kleber, 2003, Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease, Am Heart J, 145, 614, 10.1067/mhj.2003.189 · DOI
  173. Tebbe, 2011, Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study, Am Heart J, 161, 322, 10.1016/j.ahj.2010.10.005 · DOI
  174. Gray, 2008, Noninvasive ventilation in acute cardiogenic pulmonary edema, N Engl J Med, 359, 142, 10.1056/NEJMoa0707992 · DOI
  175. Cotter, 1998, Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema, Lancet, 351, 389, 10.1016/S0140-6736(97)08417-1 · DOI
  176. 2002, Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial, JAMA, 287, 1531
  177. Cohn, 1982, Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study, N Engl J Med, 306, 1129, 10.1056/NEJM198205133061902 · DOI
  178. Mehta, 2005, Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials, JAMA, 293, 2908, 10.1001/jama.293.23.2908 · DOI
  179. 1994, Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, Lancet, 343, 311, 10.1016/S0140-6736(94)91161-4 · DOI
  180. Dargie, 2001, Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial, Lancet, 357, 1385, 10.1016/S0140-6736(00)04560-8 · DOI · Paper page
  181. Park, 2010, Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction, Heart, 96, 533, 10.1136/hrt.2009.175257 · DOI
  182. Rosenberg, 2005, Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature, Cardiovasc Drugs Ther, 19, 301, 10.1007/s10557-005-3350-2 · DOI
  183. Channer, 1994, Combination diuretic treatment in severe heart failure: a randomised controlled trial, Br Heart J, 71, 146, 10.1136/hrt.71.2.146 · DOI
  184. Tan, 1988, Detrimental haemodynamic effects of cyclizine in heart failure, Lancet, 1, 560, 10.1016/S0140-6736(88)91354-2 · DOI
  185. O'Connor, 2011, Effect of nesiritide in patients with acute decompensated heart failure, N Engl J Med, 365, 32, 10.1056/NEJMoa1100171 · DOI
  186. van de Borne, 1998, Dopamine depresses minute ventilation in patients with heart failure, Circulation, 98, 126, 10.1161/01.CIR.98.2.126 · DOI
  187. Gheorghiade, 2007, Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials, JAMA, 297, 1332, 10.1001/jama.297.12.1332 · DOI · Paper page
  188. Sjauw, 2009, A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?, Eur Heart J, 30, 459, 10.1093/eurheartj/ehn602 · DOI
  189. Costanzo, 2010, Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD, J Card Fail, 16, 277, 10.1016/j.cardfail.2009.12.009 · DOI
  190. Shah, 2005, Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials, JAMA, 294, 1664, 10.1001/jama.294.13.1664 · DOI
  191. Shepperd, 2010, Discharge planning from hospital to home, Cochrane Database Syst Rev, (1), CD000313
  192. Phillips, 2004, Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis, JAMA, 291, 1358, 10.1001/jama.291.11.1358 · DOI · Paper page
  193. McDonagh, 2011, European Society of Cardiology Heart Failure Association Standards for delivering heart failure care, Eur J Heart Fail, 13, 235, 10.1093/eurjhf/hfq221 · DOI
  194. Hamm, 2011, ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC), Eur Heart J, 32, 2999, 10.1093/eurheartj/ehr236 · DOI
  195. Van de Werf, 2008, Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology, Eur Heart J, 29, 2909, 10.1093/eurheartj/ehn416 · DOI
  196. Torbicki, 2008, Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC), Eur Heart J, 29, 2276, 10.1093/eurheartj/ehn310 · DOI
  197. Galie, 2009, Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT), Eur Heart J, 30, 2493, 10.1093/eurheartj/ehp297 · DOI
  198. Mebazaa, 2010, Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery, Crit Care, 14, 201, 10.1186/cc8153 · DOI
  199. Sliwa, 2010, Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy, Eur J Heart Fail, 12, 767, 10.1093/eurjhf/hfq120 · DOI
  200. European Society of Gynecology; Association for European Paediatric Cardiology; German Society for Gender Medicine; Authors/Task Force Members, Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L; ESC Committee for Practice Guidelines, Bax J, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Baumgartner H, Deaton C, Aguiar C, Al-Attar N, Garcia AA, Antoniou A, Coman I, Elkayam U, Gomez-Sanchez MA, Gotcheva N, Hilfiker-Kleiner D, Kiss RG, Kitsiou A, Konings KT, Lip GY, Manolis A, Mebaaza A, Mintale I, Morice MC, Mulder BJ, Pasquet A, Price S, Priori SG, Salvador MJ, Shotan A, Silversides CK, Skouby SO, Stein JI, Tornos P, Vejlstrup N, Walker F, Warnes C, 2011, ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC), Eur Heart J, 32, 3147, 10.1093/eurheartj/ehr218 · DOI · Paper page

200 of 225 shown

Cited by

Sorted by citations

Items 101–105 of 105

Metadata

Authors
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., Gomez-Sanchez, M. A., Jaarsma, T., Køber, L., Lip, G. Y. H., Maggioni, A. P., Parkhomenko, A., Pieske, B. M., Popescu, B. A., Rønnevik, P. K., Rutten, F. H., Schwitter, J., Seferovic, P., Stepinska, J., Trindade, P. T., Voors, A. A., Zannad, F., Zeiher, A., ESC Committee for Practice Guidelines (CPG), Bax, J. J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., Knuuti, J., Kolh, P., McDonagh, T., Moulin, C., Popescu, B. A., Reiner, Ž., Sechtem, U., Sirnes, P. A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S., Reviewers, D., McDonagh, T., Sechtem, U., Bonet, L. A., Avraamides, P., Ben Lamin, H. A., Brignole, M., Coca, A., Cowburn, P., Dargie, H., Elliott, P., Flachskampf, F. A., Guida, G. F., Hardman, S., Iung, B., Merkely, B., Mueller, C., Nanas, J. N., Nielsen, O. W., Ørn, S., Parissis, J. T., & Ponikowski, P.
Affiliations
  • University of Glasgow (GB)
  • The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org/guidelines
ORCID
Venue
European Heart Journal
Publisher
Oxford University Press (OUP)
Published
2012-05-18
Volume
33
Issue
14
Pages
1787-1847
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
DOI
10.1093/eurheartj/ehs104
OpenAlex
W2148910374
Cited by
6,879
References
48
Citations by year
2026: 44 · 2025: 108 · 2024: 144 · 2023: 186 · 2022: 195 · 2021: 247 · 2020: 309 · 2019: 342 · 2018: 435 · 2017: 640 · 2016: 1115 · 2015: 1170 · 2014: 1039 · 2013: 767 · 2012: 123
FWCI
637.72
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
  • IRIS (submittedVersion)
  • Open Repository and Bibliography (University of Liège) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
heart failure, acute heart failure, chronic heart failure, diagnosis, treatment
MeSH terms
Acute Disease, Algorithms, Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Cardiotonic Agents, Chronic Disease, Diuretics, Drug Combinations, Electrocardiography, Exercise Test, Genetic Testing, Heart Failure, Humans, Terminology as Topic, Prognosis, Stroke Volume, Thromboembolism, Fatty Acids, Omega-3, Comorbidity, Defibrillators, Implantable, Ventricular Dysfunction, Left, Clinical Laboratory Techniques, Therapies, Investigational, Natriuretic Peptides, Cardiac Imaging Techniques, Cardiac Resynchronization Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review